Tag: axs 05
April 26, 2018
Axsome Therapeutics Announces Interim Analysis of STRIDE-1 Trial
Shares of Axsome increased nearly 20 percent after the announcement, but evened out to an overall 13.21-percent increase to $3. April 26, 2018
Axsome Therapeutics Announces Positive Outcome of Interim Analysis of STRIDE-1 Phase 3 Trial of AXS-05
Axsome Therapeutics (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today...
March 13, 2018
Investing in Alzheimer’s Treatments
What is the best way to start investing in Alzheimer's treatments? The space has proven difficult for companies to break... September 5, 2016